A Phase 3 interventional study of Levetiracetam in Epilepsy, Partial, sponsored by UCB Pharma. Completed. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2024-02-09.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 8th largest by enrollment, is the only one that started in 1998, is one of 10 in phase 3, and was the 2nd registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: Up to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 173 across the 18 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
29 studies in Epilepsies, Partial by UCB S.A.: none open now, none under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 29 studies in Epilepsies, Partial by UCB S.A., this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 1998, is one of 11 in phase 3, and was the 2nd registered.
UCB S.A.’s Epilepsies, Partial studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 29 in Epilepsies, Partial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is approved for use in children or until the completion of the development program for pediatrics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects had previously participated in study N159 in which they had received Placebo (PBO).
Drug: Levetiracetam
Subjects had previously participated in study N159 in which they had received Levetiracetam (LEV).
Drug: Levetiracetam
Subjects had previously participated in study N01010 or study N151 in which they had received Levetiracetam (LEV).
Drug: Levetiracetam
Subjects had previously participated in study N01052 in which they had received Levetiracetam (LEV).
Drug: Levetiracetam
* Pharmaceutical form: Oral tablets and oral solution * Route of administration: Oral use
Also known as: Keppra
Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period
Percentage change from Baseline of partial onset (Type I) seizure frequency over the Treatment Period standardized to 1 week Period. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures). Negative values indicate an improvement from Baseline.
Time frame: During the Treatment Period (an average of 2 years), compared to Baseline
Percentage Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period
Percentage change from Baseline in total (type I, II, III) seizure frequency over the Treatment Period standardized to 1 week Period. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification. Negative values indicate an improvement from Baseline.
Time frame: During the Treatment Period (an average of 2 years), compared to Baseline
Absolute Change From Baseline in Partial Onset (Type I) Seizure Frequency Over Time During the Treatment Period
Absolute change from Baseline of Partial onset (Type I) seizure frequency over the Treatment Period standardized to 1 week Period. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures). Negative values indicate an improvement from Baseline.
Time frame: During the Treatment Period (an average of 2 years), compared to Baseline
Absolute Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period
Absolute change from Baseline in total (type I, II, III) seizure frequency over the Treatment Period standardized to 1 week period. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification. Negative values indicate improvement from Baseline.
Time frame: During the Treatment Period (an average of 2 years), compared to Baseline
At Least 50% Responder Rate in Partial Onset (Type I) Seizure Frequency From Baseline Per Week During the Treatment Period
At least 50% responder rate in Partial Onset (Type I) Seizure Frequency per Week over the Treatment Period is defined as the percentage of subjects with a reduction from baseline in Partial Onset (Type I) seizure frequency of at least 50%. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures).
Time frame: During the Treatment Period (an average of 2 years), compared to Baseline
At Least 50% Responder Rate in Total (Type I, II, III) Seizure Frequency From Baseline Per Week During the Treatment Period
At least 50% responder rate in total (Type I, II, III) Seizure Frequency per Week over the Treatment Period is defined as the percentage of subjects with a reduction from baseline in total (Type I, II, III) seizure frequency of at least 50%. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification.
Time frame: During the Treatment Period (an average of 2 years), compared to Baseline
Number of Subjects Who Are Seizure-free for at Least 7 Days During the Treatment Period
A day was considered seizure-free if no seizures were reported for 24 hours.
Time frame: During the Treatment Period (an average of 2 years)
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 0)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: Day 0 (beginning day of the maintenance phase)
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 1 - <= 2 Months)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: Day 1 - <= 2 months of the Maintenance Phase
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 2 Months - <= 4 Months)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: > 2 months - <= 4 months of the Maintenance Phase
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 4 Months - <= 6 Months)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: > 4 months - <= 6 months of the Maintenance Phase
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 6 Months - <= 8 Months)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: > 6 months - <= 8 months of the Maintenance Phase
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 8 Months - <= 10 Months)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: > 8 months - <= 10 months of the Maintenance Phase
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 10 Months - <= 12 Months)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: > 10 months - <= 12 months of the Maintenance Phase
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 12 Months - <= 14 Months)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: > 12 months - <= 14 months of the Maintenance Phase
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 14 Months - <= 16 Months)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: > 14 months - <= 16 months of the Maintenance Phase
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 16 Months - <= 18 Months)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: > 16 months - <= 18 months of the Maintenance Phase
Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 18 Months - <= 20 Months)
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
Time frame: > 18 months - <= 20 months of the Maintenance Phase
Number of Seizures by Type During the Treatment Period
Number of following seizure types were assessed: Total seizures (Type I, II, III), Total Type I seizures, Total Type II seizures, Total Type III seizures
Time frame: During the Treatment Period (an average of 2 years)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 1
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The Global Evaluation Scale (GES) is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit). The reference time point for Visit 1 is in the respective feeder study of the participant.
Time frame: Visit 1 (Screening Visit (Week 0))
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 1
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The Global Evaluation Scale (GES) is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Titration Visit 1 (Week 2)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 2
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Titration Visit 2 (Week 4)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 3
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Titration Visit 3 (Week 6)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 2
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 2 (Month 2)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 3
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 3 (Month 4)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 4
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 4 (Month 6)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 5
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 5 (Month 9)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 6
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 6 (Month 12)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 7
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 7 (Month 15)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 8
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 8 (Month 18)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 9
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 9 (Month 21)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 10
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 10 (Month 24)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 11
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 11 (Month 27)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 12
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 12 (Month 30)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 13
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 13 (Month 33)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 14
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 14 (Month 36)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 15
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 15 (Month 39)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 16
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 16 (Month 42)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 17
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 17 (Month 45)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 18
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 18 (Month 48)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 19
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 19 (Month 51)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 20
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 20 (Month 54)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 21
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 21 (Month 57)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 22
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 22 (Month 60)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 23
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 23 (Month 63)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 24
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 24 (Month 66)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 25
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 25 (Month 69)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 26
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 26 (Month 72)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 27
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 27 (Month 75)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 28
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 28 (Month 78)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 29
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 29 (Month 81)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 30
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 30 (Month 84)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 31
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 31 (Month 87)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Withdrawal Visit
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Withdrawal visit (up to Month 90)
Percentage of Subjects in Categories of Investigator's Rating of Change to Previous Visit in Global Evaluation Scale at Final Visit
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Final visit (up to Month 90)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 1
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit). The reference time point for Visit 1 is in the respective feeder study of the participant.
Time frame: Visit 1 (Screening Visit (Week 0))
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 1
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Titration Visit 1 (Week 2)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 2
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Titration Visit 2 (Week 4)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Titration Visit 3
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Titration Visit 3 (Week 6)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 2
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 2 (Month 2)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 3
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 3 (Month 4)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 4
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 4 (Month 6)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 5
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 5 (Month 9)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 6
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 6 (Month 12)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 7
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 7 (Month 15)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 8
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 8 (Month 18)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 9
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 9 (Month 21)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 10
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 10 (Month 24)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 11
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 11 (Month 27)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 12
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 12 (Month 30)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 13
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 13 (Month 33)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 14
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 14 (Month 36)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 15
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 15 (Month 39)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 16
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 16 (Month 42)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 17
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 17 (Month 45)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 18
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 18 (Month 48)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 19
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 19 (Month 51)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 20
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 20 (Month 54)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 21
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 21 (Month 57)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 22
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 22 (Month 60)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 23
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 23 (Month 63)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 24
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 24 (Month 66)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 25
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 25 (Month 69)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 26
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 26 (Month 72)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 27
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 27 (Month 75)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 28
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 28 (Month 78)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 29
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 29 (Month 81)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 30
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 30 (Month 84)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Visit 31
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Visit 31 (Month 87)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Withdrawal Visit
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Withdrawal visit (up to Month 90)
Percentage of Subjects in Categories of Parent/Legal Guardian's Rating of Change to Previous Visit in Global Evaluation Scale at Final Visit
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
Time frame: Final visit (up to Month 90)
The study started to enroll patients in February 1998 and concluded in January 2006.
| Milestone | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Started | 79 | 89 | 41 | 14 |
| Completed | 24 | 27 | 17 | 6 |
| Not completed | 55 | 62 | 24 | 8 |
| Withdrew: Protocol violation | 7 | 8 | 3 | 1 |
| Withdrew: Adverse event | 8 | 2 | 2 | 3 |
| Withdrew: Lack of efficacy | 6 | 11 | 9 | 0 |
| Withdrew: Withdrawal by subject | 7 | 10 | 5 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 1 |
| Withdrew: Site/investigator discontinued the study | 5 | 5 | 2 | 0 |
| Withdrew: Decision of parent(s) | 1 | 2 | 0 | 0 |
| Withdrew: Decision of parent(s) and investigator | 3 | 0 | 0 | 0 |
| Withdrew: Loss/ incompleteness of efficacy | 12 | 12 | 2 | 2 |
| Withdrew: Investigator decision | 1 | 0 | 0 | 1 |
| Withdrew: Subject relocated | 2 | 2 | 1 | 0 |
| Withdrew: Subject continues keppra through prescriptions | 0 | 4 | 0 | 0 |
| Withdrew: Convenience | 0 | 1 | 0 | 0 |
| Withdrew: Subject entered new drug study | 0 | 1 | 0 | 0 |
| Withdrew: Subject to undergo surgery for seizures | 0 | 1 | 0 | 0 |
| Withdrew: Lack of ease of swallowing | 0 | 1 | 0 | 0 |
Percentage change from Baseline of partial onset (Type I) seizure frequency over the Treatment Period standardized to 1 week Period. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures). Negative values indicate an improvement from Baseline.
| percentage of change | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period | -66.4 (-90.0 to -22.3) | -47.8 (-76.2 to -25.4) | -66.4 (-93.6 to -5.6) | — |
Percentage change from Baseline in total (type I, II, III) seizure frequency over the Treatment Period standardized to 1 week Period. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification. Negative values indicate an improvement from Baseline.
| percentage of change | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Percentage Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period | -66.4 (-90.0 to -25.2) | -45.7 (-73.6 to -17.4) | -65.9 (-93.1 to -5.6) | — |
Absolute change from Baseline of Partial onset (Type I) seizure frequency over the Treatment Period standardized to 1 week Period. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures). Negative values indicate an improvement from Baseline.
| partial seizure frequency per week | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Absolute Change From Baseline in Partial Onset (Type I) Seizure Frequency Over Time During the Treatment Period | -2.1 (-7.4 to -0.3) | -1.6 (-6.6 to -0.6) | -1.5 (-7.4 to 0.0) | — |
Absolute change from Baseline in total (type I, II, III) seizure frequency over the Treatment Period standardized to 1 week period. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification. Negative values indicate improvement from Baseline.
| partial seizure frequency per week | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Absolute Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period | -2.1 (-7.4 to -0.6) | -1.5 (-6.4 to -0.5) | -1.1 (-7.3 to 0.0) | — |
At least 50% responder rate in Partial Onset (Type I) Seizure Frequency per Week over the Treatment Period is defined as the percentage of subjects with a reduction from baseline in Partial Onset (Type I) seizure frequency of at least 50%. According to the ILAE 1981 classification, seizures can be classified into one of the following three groups: Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| At Least 50% Responder Rate in Partial Onset (Type I) Seizure Frequency From Baseline Per Week During the Treatment Period | 58.4 | 47.7 | 62.2 | — |
At least 50% responder rate in total (Type I, II, III) Seizure Frequency per Week over the Treatment Period is defined as the percentage of subjects with a reduction from baseline in total (Type I, II, III) seizure frequency of at least 50%. Seizures were categorized in Type I (partial onset seizures), Type II (generalized seizures) and Type III (unclassified seizures) according to the ILAE 1981 classification.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| At Least 50% Responder Rate in Total (Type I, II, III) Seizure Frequency From Baseline Per Week During the Treatment Period | 58.4 | 46.6 | 62.2 | — |
A day was considered seizure-free if no seizures were reported for 24 hours.
| Participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Number of Subjects Who Are Seizure-free for at Least 7 Days During the Treatment Period | 74 | 73 | 40 | 10 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 0) | 74.0 | 64.0 | 75.0 | 38.5 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (Day 1 - <= 2 Months) | 16.4 | 15.1 | 27.5 | 23.1 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 2 Months - <= 4 Months) | 12.3 | 12.8 | 17.5 | 23.1 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 4 Months - <= 6 Months) | 11.0 | 9.3 | 15.0 | 11.5 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 6 Months - <= 8 Months) | 8.2 | 4.7 | 12.5 | 11.5 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 8 Months - <= 10 Months) | 5.5 | 3.5 | 10.0 | 11.5 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 10 Months - <= 12 Months) | 1.4 | 3.5 | 7.5 | 11.5 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 12 Months - <= 14 Months) | 1.4 | 2.3 | 5.0 | 11.5 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 14 Months - <= 16 Months) | 1.4 | 2.3 | 5.0 | 11.5 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 16 Months - <= 18 Months) | 1.4 | 2.3 | 2.5 | 11.5 |
A time interval was considered seizure-free if no seizures were reported in that time interval. The Treatment Period consisted of a 6-week Titration Phase and a Maintenance Phase lasting until market approval or completion of development of levetiracetam for the pediatric indication.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Cumulative Percentage of Subjects Who Are Continuously Seizure Free by Time Interval (> 18 Months - <= 20 Months) | 1.4 | 2.3 | 2.5 | 11.5 |
Number of following seizure types were assessed: Total seizures (Type I, II, III), Total Type I seizures, Total Type II seizures, Total Type III seizures
| seizures | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Total seizures (Type I, II, III) | 42132 | 70121 | 24232 | 19914 |
| Total Type I seizures | 39147 | 57464 | 24089 | 13675 |
| Total Type II seizures | 2142 | 12656 | 142 | 6239 |
| Total Type III seizures | 843 | 1 | 1 | 0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The Global Evaluation Scale (GES) is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit). The reference time point for Visit 1 is in the respective feeder study of the participant.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 7.7 | 11.2 | 29.3 | 0.0 |
| Moderate improvement | 21.8 | 18.0 | 12.2 | 0.0 |
| Slight improvement | 12.8 | 24.7 | 19.5 | 0.0 |
| No change | 47.4 | 40.4 | 26.8 | 100.0 |
| Slight worsening | 5.1 | 5.6 | 12.2 | 0.0 |
| Moderate worsening | 3.8 | 0.0 | 0.0 | 0.0 |
| Marked worsening | 0.0 | 0.0 | 0.0 | 0.0 |
| Not done | 1.3 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The Global Evaluation Scale (GES) is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 14.9 | 6.1 | — | — |
| Moderate improvement | 14.9 | 14.6 | — | — |
| Slight improvement | 32.4 | 18.3 | — | — |
| No change | 33.8 | 47.6 | — | — |
| Slight worsening | 4.1 | 9.8 | — | — |
| Moderate worsening | 0.0 | 2.4 | — | — |
| Marked worsening | 0.0 | 0.0 | — | — |
| Not done | 0.0 | 1.2 | — | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 10.7 | 13.1 | — | — |
| Moderate improvement | 20.0 | 8.3 | — | — |
| Slight improvement | 20.0 | 15.5 | — | — |
| No change | 37.3 | 46.4 | — | — |
| Slight worsening | 9.3 | 11.9 | — | — |
| Moderate worsening | 2.7 | 2.4 | — | — |
| Marked worsening | 0.0 | 0.0 | — | — |
| Not done | 0.0 | 2.4 | — | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 10.4 | 4.1 | — | — |
| Moderate improvement | 14.9 | 8.2 | — | — |
| Slight improvement | 17.9 | 21.9 | — | — |
| No change | 41.8 | 47.9 | — | — |
| Slight worsening | 7.5 | 9.6 | — | — |
| Moderate worsening | 4.5 | 4.1 | — | — |
| Marked worsening | 0.0 | 1.4 | — | — |
| Not done | 3.0 | 2.7 | — | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 4.1 | 8.3 | 20.5 | 16.7 |
| Moderate improvement | 15.1 | 14.3 | 20.5 | 16.7 |
| Slight improvement | 26.0 | 17.9 | 25.6 | 25.0 |
| No change | 34.2 | 46.4 | 28.2 | 16.7 |
| Slight worsening | 15.1 | 8.3 | 2.6 | 0.0 |
| Moderate worsening | 2.7 | 2.4 | 2.6 | 8.3 |
| Marked worsening | 1.4 | 2.4 | 0.0 | 16.7 |
| Not done | 1.4 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 4.4 | 6.5 | 15.8 | 20.0 |
| Moderate improvement | 7.4 | 3.9 | 15.8 | 0.0 |
| Slight improvement | 20.6 | 14.3 | 26.3 | 30.0 |
| No change | 41.2 | 50.6 | 34.2 | 40.0 |
| Slight worsening | 20.6 | 20.8 | 7.9 | 10.0 |
| Moderate worsening | 5.9 | 3.9 | 0.0 | 0.0 |
| Marked worsening | 0.0 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 4.8 | 4.0 | 14.3 | 10.0 |
| Moderate improvement | 6.3 | 10.7 | 17.1 | 10.0 |
| Slight improvement | 23.8 | 28.0 | 8.6 | 10.0 |
| No change | 42.9 | 34.7 | 42.9 | 60.0 |
| Slight worsening | 12.7 | 17.3 | 14.3 | 10.0 |
| Moderate worsening | 7.9 | 4.0 | 2.9 | 0.0 |
| Marked worsening | 0.0 | 0.0 | 0.0 | 0.0 |
| Not done | 1.6 | 1.3 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 3.4 | 6.2 | 3.1 | 0.0 |
| Moderate improvement | 13.6 | 6.2 | 15.6 | 22.2 |
| Slight improvement | 25.4 | 18.5 | 9.4 | 22.2 |
| No change | 35.6 | 46.2 | 53.1 | 44.4 |
| Slight worsening | 18.6 | 16.9 | 12.5 | 0.0 |
| Moderate worsening | 3.4 | 4.6 | 6.3 | 11.1 |
| Marked worsening | 0.0 | 1.5 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 5.6 | 1.6 | 10.7 | 11.1 |
| Moderate improvement | 16.7 | 13.1 | 14.3 | 11.1 |
| Slight improvement | 22.2 | 19.7 | 17.9 | 22.2 |
| No change | 29.6 | 41.0 | 39.3 | 55.6 |
| Slight worsening | 20.4 | 18.0 | 14.3 | 0.0 |
| Moderate worsening | 3.7 | 6.6 | 3.6 | 0.0 |
| Marked worsening | 1.9 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 12.8 | 9.6 | 3.6 | 0.0 |
| Moderate improvement | 4.3 | 13.5 | 7.1 | 0.0 |
| Slight improvement | 23.4 | 11.5 | 14.3 | 37.5 |
| No change | 42.6 | 40.4 | 39.3 | 37.5 |
| Slight worsening | 12.8 | 21.2 | 25.0 | 12.5 |
| Moderate worsening | 2.1 | 1.9 | 10.7 | 12.5 |
| Marked worsening | 2.1 | 1.9 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 10.0 | 3.9 | 3.6 | 16.7 |
| Moderate improvement | 5.0 | 11.8 | 17.9 | 0.0 |
| Slight improvement | 20.0 | 23.5 | 14.3 | 16.7 |
| No change | 37.5 | 39.2 | 42.9 | 66.7 |
| Slight worsening | 25.0 | 17.6 | 14.3 | 0.0 |
| Moderate worsening | 2.5 | 3.9 | 7.1 | 0.0 |
| Marked worsening | 0.0 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 5.1 | 8.2 | 14.8 | 0.0 |
| Moderate improvement | 7.7 | 14.3 | 11.1 | 0.0 |
| Slight improvement | 12.8 | 22.4 | 22.2 | 0.0 |
| No change | 48.7 | 34.7 | 33.3 | 80.0 |
| Slight worsening | 23.1 | 18.4 | 7.4 | 20.0 |
| Moderate worsening | 2.6 | 0.0 | 7.4 | 0.0 |
| Marked worsening | 0.0 | 2.0 | 3.7 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 5.7 | 6.4 | 4.0 | 0.0 |
| Moderate improvement | 8.6 | 12.8 | 8.0 | 0.0 |
| Slight improvement | 22.9 | 17.0 | 20.0 | 0.0 |
| No change | 45.7 | 51.1 | 48.0 | 66.7 |
| Slight worsening | 11.4 | 12.8 | 20.0 | 16.7 |
| Moderate worsening | 5.7 | 0.0 | 0.0 | 16.7 |
| Marked worsening | 0.0 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 9.4 | 2.3 | 4.5 | 0.0 |
| Moderate improvement | 9.4 | 6.8 | 22.7 | 20.0 |
| Slight improvement | 21.9 | 20.5 | 13.6 | 20.0 |
| No change | 50.0 | 45.5 | 54.5 | 60.0 |
| Slight worsening | 6.3 | 15.9 | 4.5 | 0.0 |
| Moderate worsening | 0.0 | 4.5 | 0.0 | 0.0 |
| Marked worsening | 0.0 | 2.3 | 0.0 | 0.0 |
| Not done | 3.1 | 2.3 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 6.7 | 5.1 | 0.0 | 0.0 |
| Moderate improvement | 6.7 | 15.4 | 5.6 | 0.0 |
| Slight improvement | 33.3 | 25.6 | 11.1 | 25.0 |
| No change | 33.3 | 43.6 | 61.1 | 75.0 |
| Slight worsening | 16.7 | 7.7 | 11.1 | 0.0 |
| Moderate worsening | 0.0 | 2.6 | 11.1 | 0.0 |
| Marked worsening | 3.3 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 3.8 | 3.3 | 0.0 | 0.0 |
| Moderate improvement | 7.7 | 6.7 | 11.1 | 0.0 |
| Slight improvement | 34.6 | 23.3 | 22.2 | 50.0 |
| No change | 38.5 | 46.7 | 55.6 | 50.0 |
| Slight worsening | 15.4 | 16.7 | 11.1 | 0.0 |
| Moderate worsening | 0.0 | 3.3 | 0.0 | 0.0 |
| Marked worsening | 0.0 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 13.3 | 4.2 | 0.0 | — |
| Moderate improvement | 0.0 | 0.0 | 0.0 | — |
| Slight improvement | 33.3 | 16.7 | 11.1 | — |
| No change | 40.0 | 45.8 | 66.7 | — |
| Slight worsening | 13.3 | 25.0 | 11.1 | — |
| Moderate worsening | 0.0 | 8.3 | 11.1 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 6.7 | 0.0 | 0.0 | — |
| Moderate improvement | 0.0 | 0.0 | 14.3 | — |
| Slight improvement | 26.7 | 28.6 | 14.3 | — |
| No change | 46.7 | 61.9 | 57.1 | — |
| Slight worsening | 6.7 | 9.5 | 14.3 | — |
| Moderate worsening | 13.3 | 0.0 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 0.0 | 0.0 | 0.0 | — |
| Moderate improvement | 0.0 | 5.6 | 0.0 | — |
| Slight improvement | 35.7 | 11.1 | 14.3 | — |
| No change | 42.9 | 61.1 | 85.7 | — |
| Slight worsening | 14.3 | 16.7 | 0.0 | — |
| Moderate worsening | 7.1 | 0.0 | 0.0 | — |
| Marked worsening | 0.0 | 5.6 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 7.7 | 11.8 | 0.0 | — |
| Moderate improvement | 0.0 | 0.0 | 16.7 | — |
| Slight improvement | 38.5 | 17.6 | 0.0 | — |
| No change | 53.8 | 47.1 | 83.3 | — |
| Slight worsening | 0.0 | 23.5 | 0.0 | — |
| Moderate worsening | 0.0 | 0.0 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 7.7 | 15.4 | 16.7 | — |
| Moderate improvement | 0.0 | 0.0 | 0.0 | — |
| Slight improvement | 15.4 | 30.8 | 16.7 | — |
| No change | 46.2 | 38.5 | 50.0 | — |
| Slight worsening | 30.8 | 15.4 | 0.0 | — |
| Moderate worsening | 0.0 | 0.0 | 16.7 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 9.1 | 7.7 | 0.0 | — |
| Moderate improvement | 0.0 | 7.7 | 0.0 | — |
| Slight improvement | 18.2 | 15.4 | 40.0 | — |
| No change | 54.5 | 46.2 | 60.0 | — |
| Slight worsening | 18.2 | 23.1 | 0.0 | — |
| Moderate worsening | 0.0 | 0.0 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 0.0 | 8.3 | 0.0 | — |
| Moderate improvement | 9.1 | 0.0 | 0.0 | — |
| Slight improvement | 18.2 | 16.7 | 0.0 | — |
| No change | 63.6 | 58.3 | 100.0 | — |
| Slight worsening | 9.1 | 8.3 | 0.0 | — |
| Moderate worsening | 0.0 | 8.3 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 22.2 | 0.0 | 0.0 | — |
| Moderate improvement | 0.0 | 12.5 | 0.0 | — |
| Slight improvement | 22.2 | 12.5 | 20.0 | — |
| No change | 55.6 | 62.5 | 80.0 | — |
| Slight worsening | 0.0 | 12.5 | 0.0 | — |
| Moderate worsening | 0.0 | 0.0 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 33.3 | 0.0 | 0.0 | — |
| Moderate improvement | 0.0 | 0.0 | 20.0 | — |
| Slight improvement | 0.0 | 0.0 | 20.0 | — |
| No change | 33.3 | 75.0 | 60.0 | — |
| Slight worsening | 33.3 | 0.0 | 0.0 | — |
| Moderate worsening | 0.0 | 25.0 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 0.0 | 0.0 | 0.0 | — |
| Moderate improvement | 0.0 | 0.0 | 20.0 | — |
| Slight improvement | 50.0 | 100.0 | 20.0 | — |
| No change | 50.0 | 0.0 | 40.0 | — |
| Slight worsening | 0.0 | 0.0 | 0.0 | — |
| Moderate worsening | 0.0 | 0.0 | 20.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 0.0 | — | 20.0 | — |
| Moderate improvement | 0.0 | — | 0.0 | — |
| Slight improvement | 0.0 | — | 0.0 | — |
| No change | 100.0 | — | 80.0 | — |
| Slight worsening | 0.0 | — | 0.0 | — |
| Moderate worsening | 0.0 | — | 0.0 | — |
| Marked worsening | 0.0 | — | 0.0 | — |
| Not done | 0.0 | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 0.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 100.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 25.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 75.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 25.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 75.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 0.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 100.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 0.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 75.0 | — |
| Slight worsening | — | — | 25.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 0.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 100.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 0.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 100.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 5.9 | 0.0 | 0.0 | 0.0 |
| Moderate improvement | 5.9 | 7.1 | 0.0 | 0.0 |
| Slight improvement | 5.9 | 0.0 | 20.0 | 25.0 |
| No change | 41.2 | 50.0 | 0.0 | 75.0 |
| Slight worsening | 11.8 | 35.7 | 60.0 | 0.0 |
| Moderate worsening | 23.5 | 0.0 | 20.0 | 0.0 |
| Marked worsening | 5.9 | 7.1 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the investigator applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 4.3 | 3.7 | 2.4 | 7.7 |
| Moderate improvement | 11.6 | 6.2 | 17.1 | 0.0 |
| Slight improvement | 23.2 | 9.9 | 14.6 | 7.7 |
| No change | 36.2 | 61.7 | 51.2 | 69.2 |
| Slight worsening | 17.4 | 9.9 | 4.9 | 15.4 |
| Moderate worsening | 4.3 | 6.2 | 9.8 | 0.0 |
| Marked worsening | 1.4 | 0.0 | 0.0 | 0.0 |
| Not done | 1.4 | 2.5 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit). The reference time point for Visit 1 is in the respective feeder study of the participant.
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 12.8 | 18.0 | 29.3 | 0.0 |
| Moderate improvement | 16.7 | 15.7 | 14.6 | 0.0 |
| Slight improvement | 17.9 | 19.1 | 14.6 | 0.0 |
| No change | 41.0 | 38.2 | 24.4 | 92.9 |
| Slight worsening | 7.7 | 7.9 | 17.1 | 7.1 |
| Moderate worsening | 3.8 | 0.0 | 0.0 | 0.0 |
| Marked worsening | 0.0 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 1.1 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 17.6 | 11.0 | — | — |
| Moderate improvement | 18.9 | 11.0 | — | — |
| Slight improvement | 32.4 | 17.1 | — | — |
| No change | 25.7 | 48.8 | — | — |
| Slight worsening | 4.1 | 8.5 | — | — |
| Moderate worsening | 0.0 | 1.2 | — | — |
| Marked worsening | 0.0 | 0.0 | — | — |
| Not done | 1.4 | 2.4 | — | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 17.3 | 16.7 | — | — |
| Moderate improvement | 16.0 | 10.7 | — | — |
| Slight improvement | 20.0 | 15.5 | — | — |
| No change | 36.0 | 39.3 | — | — |
| Slight worsening | 6.7 | 15.5 | — | — |
| Moderate worsening | 2.7 | 1.2 | — | — |
| Marked worsening | 0.0 | 0.0 | — | — |
| Not done | 1.3 | 1.2 | — | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 10.4 | 4.1 | — | — |
| Moderate improvement | 9.0 | 12.3 | — | — |
| Slight improvement | 20.9 | 27.4 | — | — |
| No change | 43.3 | 41.1 | — | — |
| Slight worsening | 9.0 | 8.2 | — | — |
| Moderate worsening | 3.0 | 4.1 | — | — |
| Marked worsening | 1.5 | 1.4 | — | — |
| Not done | 3.0 | 1.4 | — | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 6.8 | 13.1 | 25.6 | 16.7 |
| Moderate improvement | 17.8 | 11.9 | 15.4 | 8.3 |
| Slight improvement | 21.9 | 16.7 | 20.5 | 41.7 |
| No change | 30.1 | 45.2 | 17.9 | 8.3 |
| Slight worsening | 17.8 | 4.8 | 17.9 | 0.0 |
| Moderate worsening | 2.7 | 4.8 | 2.6 | 8.3 |
| Marked worsening | 2.7 | 1.2 | 0.0 | 16.7 |
| Not done | 0.0 | 2.4 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 8.8 | 6.5 | 18.4 | 20.0 |
| Moderate improvement | 5.9 | 6.5 | 15.8 | 20.0 |
| Slight improvement | 16.2 | 13.0 | 18.4 | 20.0 |
| No change | 38.2 | 48.1 | 36.8 | 30.0 |
| Slight worsening | 19.1 | 22.1 | 7.9 | 10.0 |
| Moderate worsening | 10.3 | 3.9 | 2.6 | 0.0 |
| Marked worsening | 1.5 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 4.8 | 8.0 | 20.0 | 20.0 |
| Moderate improvement | 7.9 | 6.7 | 14.3 | 0.0 |
| Slight improvement | 22.2 | 29.3 | 5.7 | 20.0 |
| No change | 39.7 | 33.3 | 37.1 | 50.0 |
| Slight worsening | 19.0 | 17.3 | 17.1 | 10.0 |
| Moderate worsening | 4.8 | 5.3 | 5.7 | 0.0 |
| Marked worsening | 1.6 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 6.8 | 10.8 | 9.4 | 11.1 |
| Moderate improvement | 10.2 | 6.2 | 9.4 | 33.3 |
| Slight improvement | 25.4 | 12.3 | 9.4 | 11.1 |
| No change | 33.9 | 46.2 | 50.0 | 33.3 |
| Slight worsening | 20.3 | 15.4 | 9.4 | 0.0 |
| Moderate worsening | 0.0 | 6.2 | 12.5 | 11.1 |
| Marked worsening | 3.4 | 3.1 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 7.4 | 8.2 | 14.3 | 11.1 |
| Moderate improvement | 9.3 | 13.1 | 14.3 | 11.1 |
| Slight improvement | 25.9 | 23.0 | 14.3 | 22.2 |
| No change | 33.3 | 34.4 | 39.3 | 55.6 |
| Slight worsening | 18.5 | 11.5 | 14.3 | 0.0 |
| Moderate worsening | 3.7 | 8.2 | 3.6 | 0.0 |
| Marked worsening | 1.9 | 1.6 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 10.6 | 19.2 | 7.1 | 0.0 |
| Moderate improvement | 10.6 | 9.6 | 7.1 | 0.0 |
| Slight improvement | 23.4 | 7.7 | 10.7 | 37.5 |
| No change | 29.8 | 40.4 | 42.9 | 37.5 |
| Slight worsening | 19.1 | 15.4 | 25.0 | 12.5 |
| Moderate worsening | 4.3 | 3.8 | 3.6 | 0.0 |
| Marked worsening | 2.1 | 1.9 | 3.6 | 12.5 |
| Not done | 0.0 | 1.9 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 5.0 | 15.7 | 7.1 | 16.7 |
| Moderate improvement | 7.5 | 9.8 | 14.3 | 0.0 |
| Slight improvement | 17.5 | 17.6 | 14.3 | 16.7 |
| No change | 45.0 | 35.3 | 42.9 | 66.7 |
| Slight worsening | 22.5 | 15.7 | 10.7 | 0.0 |
| Moderate worsening | 2.5 | 3.9 | 10.7 | 0.0 |
| Marked worsening | 0.0 | 2.0 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 10.3 | 12.2 | 18.5 | 0.0 |
| Moderate improvement | 7.7 | 10.2 | 7.4 | 0.0 |
| Slight improvement | 10.3 | 14.3 | 22.2 | 40.0 |
| No change | 56.4 | 53.1 | 33.3 | 40.0 |
| Slight worsening | 10.3 | 6.1 | 3.7 | 0.0 |
| Moderate worsening | 5.1 | 2.0 | 11.1 | 20.0 |
| Marked worsening | 0.0 | 2.0 | 3.7 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 8.6 | 8.5 | 12.0 | 0.0 |
| Moderate improvement | 5.7 | 8.5 | 4.0 | 0.0 |
| Slight improvement | 22.9 | 21.3 | 20.0 | 16.7 |
| No change | 42.9 | 48.9 | 40.0 | 66.7 |
| Slight worsening | 11.4 | 10.6 | 20.0 | 0.0 |
| Moderate worsening | 5.7 | 2.1 | 0.0 | 16.7 |
| Marked worsening | 2.9 | 0.0 | 4.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 9.4 | 9.1 | 9.1 | 0.0 |
| Moderate improvement | 9.4 | 4.5 | 22.7 | 20.0 |
| Slight improvement | 18.8 | 18.2 | 9.1 | 20.0 |
| No change | 53.1 | 45.5 | 54.5 | 40.0 |
| Slight worsening | 6.3 | 11.4 | 4.5 | 20.0 |
| Moderate worsening | 0.0 | 6.8 | 0.0 | 0.0 |
| Marked worsening | 0.0 | 2.3 | 0.0 | 0.0 |
| Not done | 3.1 | 2.3 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 6.7 | 7.7 | 0.0 | 0.0 |
| Moderate improvement | 13.3 | 12.8 | 11.1 | 0.0 |
| Slight improvement | 26.7 | 20.5 | 5.6 | 25.0 |
| No change | 33.3 | 48.7 | 55.6 | 75.0 |
| Slight worsening | 16.7 | 5.1 | 16.7 | 0.0 |
| Moderate worsening | 3.3 | 2.6 | 11.1 | 0.0 |
| Marked worsening | 0.0 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 2.6 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 7.7 | 3.3 | 0.0 | 0.0 |
| Moderate improvement | 23.1 | 6.7 | 11.1 | 0.0 |
| Slight improvement | 15.4 | 23.3 | 22.2 | 25.0 |
| No change | 38.5 | 46.7 | 55.6 | 75.0 |
| Slight worsening | 15.4 | 16.7 | 11.1 | 0.0 |
| Moderate worsening | 0.0 | 3.3 | 0.0 | 0.0 |
| Marked worsening | 0.0 | 0.0 | 0.0 | 0.0 |
| Not done | 0.0 | 0.0 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 20.0 | 4.2 | 0.0 | — |
| Moderate improvement | 0.0 | 4.2 | 0.0 | — |
| Slight improvement | 26.7 | 12.5 | 11.1 | — |
| No change | 40.0 | 50.0 | 66.7 | — |
| Slight worsening | 13.3 | 20.8 | 22.2 | — |
| Moderate worsening | 0.0 | 4.2 | 0.0 | — |
| Marked worsening | 0.0 | 4.2 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 6.7 | 0.0 | 0.0 | — |
| Moderate improvement | 6.7 | 0.0 | 14.3 | — |
| Slight improvement | 40.0 | 28.6 | 14.3 | — |
| No change | 40.0 | 52.4 | 57.1 | — |
| Slight worsening | 6.7 | 9.5 | 14.3 | — |
| Moderate worsening | 0.0 | 4.8 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 4.8 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 7.1 | 0.0 | 0.0 | — |
| Moderate improvement | 21.4 | 0.0 | 0.0 | — |
| Slight improvement | 14.3 | 16.7 | 28.6 | — |
| No change | 35.7 | 55.6 | 71.4 | — |
| Slight worsening | 14.3 | 22.2 | 0.0 | — |
| Moderate worsening | 7.1 | 0.0 | 0.0 | — |
| Marked worsening | 0.0 | 5.6 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 15.4 | 11.8 | 0.0 | — |
| Moderate improvement | 0.0 | 0.0 | 16.7 | — |
| Slight improvement | 38.5 | 23.5 | 0.0 | — |
| No change | 46.2 | 41.2 | 83.3 | — |
| Slight worsening | 0.0 | 17.6 | 0.0 | — |
| Moderate worsening | 0.0 | 5.9 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 0.0 | 15.4 | 16.7 | — |
| Moderate improvement | 0.0 | 7.7 | 0.0 | — |
| Slight improvement | 23.1 | 23.1 | 16.7 | — |
| No change | 38.5 | 38.5 | 50.0 | — |
| Slight worsening | 38.5 | 15.4 | 0.0 | — |
| Moderate worsening | 0.0 | 0.0 | 16.7 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 9.1 | 7.7 | 0.0 | — |
| Moderate improvement | 0.0 | 7.7 | 0.0 | — |
| Slight improvement | 27.3 | 23.1 | 40.0 | — |
| No change | 45.5 | 38.5 | 60.0 | — |
| Slight worsening | 18.2 | 23.1 | 0.0 | — |
| Moderate worsening | 0.0 | 0.0 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 9.1 | 8.3 | 0.0 | — |
| Moderate improvement | 9.1 | 0.0 | 0.0 | — |
| Slight improvement | 9.1 | 16.7 | 0.0 | — |
| No change | 63.6 | 66.7 | 100.0 | — |
| Slight worsening | 9.1 | 0.0 | 0.0 | — |
| Moderate worsening | 0.0 | 8.3 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 22.2 | 0.0 | 0.0 | — |
| Moderate improvement | 0.0 | 0.0 | 20.0 | — |
| Slight improvement | 22.2 | 37.5 | 20.0 | — |
| No change | 55.6 | 50.0 | 60.0 | — |
| Slight worsening | 0.0 | 12.5 | 0.0 | — |
| Moderate worsening | 0.0 | 0.0 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 33.3 | 0.0 | 20.0 | — |
| Moderate improvement | 0.0 | 0.0 | 0.0 | — |
| Slight improvement | 0.0 | 0.0 | 20.0 | — |
| No change | 33.3 | 75.0 | 60.0 | — |
| Slight worsening | 33.3 | 0.0 | 0.0 | — |
| Moderate worsening | 0.0 | 25.0 | 0.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 0.0 | 0.0 | 0.0 | — |
| Moderate improvement | 50.0 | 0.0 | 20.0 | — |
| Slight improvement | 0.0 | 100.0 | 20.0 | — |
| No change | 50.0 | 0.0 | 40.0 | — |
| Slight worsening | 0.0 | 0.0 | 0.0 | — |
| Moderate worsening | 0.0 | 0.0 | 20.0 | — |
| Marked worsening | 0.0 | 0.0 | 0.0 | — |
| Not done | 0.0 | 0.0 | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 0.0 | — | 20.0 | — |
| Moderate improvement | 0.0 | — | 0.0 | — |
| Slight improvement | 0.0 | — | 0.0 | — |
| No change | 100.0 | — | 80.0 | — |
| Slight worsening | 0.0 | — | 0.0 | — |
| Moderate worsening | 0.0 | — | 0.0 | — |
| Marked worsening | 0.0 | — | 0.0 | — |
| Not done | 0.0 | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 0.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 100.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 25.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 75.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 25.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 75.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 0.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 100.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 0.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 75.0 | — |
| Slight worsening | — | — | 25.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 0.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 100.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | — | — | 0.0 | — |
| Moderate improvement | — | — | 0.0 | — |
| Slight improvement | — | — | 0.0 | — |
| No change | — | — | 100.0 | — |
| Slight worsening | — | — | 0.0 | — |
| Moderate worsening | — | — | 0.0 | — |
| Marked worsening | — | — | 0.0 | — |
| Not done | — | — | 0.0 | — |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 5.9 | 7.1 | 0.0 | 0.0 |
| Moderate improvement | 0.0 | 0.0 | 0.0 | 0.0 |
| Slight improvement | 5.9 | 0.0 | 20.0 | 25.0 |
| No change | 41.2 | 42.9 | 40.0 | 75.0 |
| Slight worsening | 29.4 | 21.4 | 20.0 | 0.0 |
| Moderate worsening | 17.6 | 14.3 | 20.0 | 0.0 |
| Marked worsening | 0.0 | 7.1 | 0.0 | 0.0 |
| Not done | 0.0 | 7.1 | 0.0 | 0.0 |
Disease evolution compared to the last visit was evaluated by the parent/legal guardian applying following categories: Marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, marked worsening, not done. The GES is a 7-point scale wherein 7 categories are ranked from 1 (marked improvement from previous visit) to 7 (marked worsening from previous visit).
| percentage of participants | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| Marked improvement | 8.7 | 7.4 | 4.9 | 7.7 |
| Moderate improvement | 14.5 | 8.6 | 12.2 | 0.0 |
| Slight improvement | 15.9 | 6.2 | 14.6 | 7.7 |
| No change | 34.8 | 58.0 | 51.2 | 69.2 |
| Slight worsening | 17.4 | 13.6 | 4.9 | 15.4 |
| Moderate worsening | 0.0 | 3.7 | 4.9 | 0.0 |
| Marked worsening | 5.8 | 1.2 | 7.3 | 0.0 |
| Not done | 2.9 | 1.2 | 0.0 | 0.0 |
Collected over Adverse events were collected from first dose in N157 to End of the Study (up to 7.5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| N159 PBO/LEV | 0/79 (0%) | 20/79 (25.3%) | 77/79 (97.5%) |
| N159 LEV/LEV | 1/89 (1.1%) | 35/89 (39.3%) | 86/89 (96.6%) |
| N01010+N151 LEV/LEV | 0/41 (0%) | 12/41 (29.3%) | 41/41 (100%) |
| N01052 LEV/LEV | 0/14 (0%) | 7/14 (50%) | 13/14 (92.9%) |
| Event | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| ConvulsionNervous system disorders | 9/79 | 7/89 | 2/41 | 4/14 |
| Procedure therapeutic epilepsyInvestigations | 2/79 | 8/89 | 5/41 | 0/14 |
| Procedure diagnostic epilepsyInvestigations | 2/79 | 9/89 | 1/41 | 0/14 |
| CystGeneral disorders | 0/79 | 0/89 | 0/41 | 1/14 |
| HypothermiaGeneral disorders | 0/79 | 0/89 | 0/41 | 1/14 |
| InfectionGeneral disorders | 0/79 | 0/89 | 0/41 | 1/14 |
| ConstipationGastrointestinal disorders | 0/79 | 0/89 | 0/41 | 1/14 |
| Gastrointestinal disorderGastrointestinal disorders | 0/79 | 0/89 | 0/41 | 1/14 |
| DehydrationMetabolism and nutrition disorders | 1/79 | 0/89 | 0/41 | 1/14 |
| Status epilepticusNervous system disorders | 1/79 | 1/89 | 0/41 | 1/14 |
| Event | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV |
|---|---|---|---|---|
| InfectionGeneral disorders | 46/79 | 48/89 | 20/41 | 10/14 |
| FeverGeneral disorders | 24/79 | 23/89 | 9/41 | 7/14 |
| Otitis mediaEar and labyrinth disorders | 17/79 | 19/89 | 9/41 | 7/14 |
| HeadacheGeneral disorders | 19/79 | 23/89 | 15/41 | 0/14 |
| NervousnessNervous system disorders | 1/79 | 5/89 | 14/41 | 2/14 |
| Accidental injuryGeneral disorders | 18/79 | 26/89 | 9/41 | 3/14 |
| AnorexiaGastrointestinal disorders | 7/79 | 8/89 | 6/41 | 4/14 |
| GastroenteritisGastrointestinal disorders | 14/79 | 8/89 | 4/41 | 4/14 |
| VomitingGastrointestinal disorders | 15/79 | 16/89 | 11/41 | 4/14 |
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 1/79 | 1/89 | 2/41 | 4/14 |
Baseline characteristics refer to the Intention-to-treat (ITT) Set which consisted of all subjects who took at least one dose of levetiracetam in study N157 excluding subjects from one site due to the unreliability of the data reported.
| Age, Categorical(Participants) | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV | Total Title |
|---|---|---|---|---|---|
| <=18 years | 79 | 89 | 41 | 14 | 223 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV | Total Title |
|---|---|---|---|---|---|
| Mean | 9.88 ± 3.46 | 10.61 ± 3.24 | 10.07 ± 2.20 | 1.62 ± 1.16 | 9.68 ± 3.72 |
| Sex: Female, Male(Participants) | N159 PBO/LEV | N159 LEV/LEV | N01010+N151 LEV/LEV | N01052 LEV/LEV | Total Title |
|---|---|---|---|---|---|
| Female | 43 | 39 | 16 | 7 | 105 |
| Male | 36 | 50 | 25 | 7 | 118 |
No study locations are listed for this record.
Plan to share: No
Ran from Jan 1998 to primary completion in Jan 2006, 95 months.
Results were first posted in Feb 2024, 18 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam